Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
株式のランク #7143
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
株価
$40.39
最終同期: 2023-08-18
時価総額
$1.70B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Chinook Therapeutics, Inc. (KDNY)

カテゴリー

Chinook Therapeutics, Inc.(KDNY)の株価履歴
終値の最高値: $40.34 (2023-08-01)

終値の最安値: $177.63 (2015-04-01)
Chinook Therapeutics, Inc. の株価履歴(2015 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.53 -12.48%
AU
$140.81 475.44%
US
$765.25 7.74%
CH